Eupraxia Pharmaceuticals (EPRX) Expected to Announce Earnings on Tuesday

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is anticipated to issue its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX stock traded down $0.01 during trading hours on Tuesday, reaching $6.50. The company had a trading volume of 78,903 shares, compared to its average volume of 268,831. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.31 and a current ratio of 19.31. The business has a fifty day moving average price of $6.46 and a 200-day moving average price of $7.27. Eupraxia Pharmaceuticals has a one year low of $5.04 and a one year high of $9.32. The firm has a market cap of $422.63 million, a PE ratio of -6.16 and a beta of 1.08.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on EPRX. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, July 15th. Wall Street Zen lowered Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Finally, Zacks Research raised Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of EPRX. Integrated Wealth Concepts LLC bought a new position in shares of Eupraxia Pharmaceuticals in the third quarter worth about $71,000. Bank of America Corp DE lifted its holdings in Eupraxia Pharmaceuticals by 402.4% during the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares in the last quarter. Guardian Wealth Advisors LLC NC purchased a new position in Eupraxia Pharmaceuticals during the fourth quarter valued at approximately $76,000. Aptus Capital Advisors LLC bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter worth approximately $76,000. Finally, Geode Capital Management LLC bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter worth approximately $105,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.